HORMONES

Sexual desire.

Bremelanotide’s evidence in a defined clinical population.

What to look for. Vyleesi’s approved indication concerns acquired, generalized HSDD in eligible premenopausal women. Check the trial population before generalizing.

FDA-approved product

PT-141

PT-141, or bremelanotide, is a melanocortin-receptor agonist. The prescription product Vyleesi treats acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women; broader libido claims need their own evidence.

Evidence in this guide: Product-specific human evidence and US prescribing information.

VYLEESI prescribing information & autoinjector instructions ↗

Read the PT-141 guide ↗